- Lyell Immunopharma (LYEL) announced it will present **new clinical and translational data** for its dual-targeting CD19/CD20 CAR T-cell candidate, **rondecabtagene autoleucel (ronde-cel)**, for aggressive large B-cell lymphoma (LBCL) at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition on **December 7, 2025**.  **[1806952_b678c6f127724e6aab4c459deda3a6ef_0]** **[1806952_b678c6f127724e6aab4c459deda3a6ef_1]** 
- As of June 27, 2025, the Phase 1/2 trial data for ronde-cel in LBCL showed **high overall response rates and complete response rates with an encouraging safety profile**.  **[1806952_b678c6f127724e6aab4c459deda3a6ef_0]** 
- Ronde-cel has been granted **Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations** by the FDA for relapsed and/or refractory diffuse LBCL in the third- or later-line setting.  **[1806952_b678c6f127724e6aab4c459deda3a6ef_0]** 
- Lyell is currently enrolling patients in the **PiNACLE single-arm registration trial** and is initiating a **randomized controlled trial** of ronde-cel in LBCL.  **[1806952_b678c6f127724e6aab4c459deda3a6ef_0]**